Stockreport

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

Imunon, Inc.  (IMNN) 
PDF DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN [Read more]